Under the Microscope: Can the Competition Commission Rein in Private Clinic Costs?

Qs & As

By Lex

For decades, the regulation of private clinics in Mauritius was largely a matter of “bricks and mortar” — ensuring that premises were sanitary and equipment was up to code under the Private Health Institutions Act 1989. However, as of April 2026, the rules of the game have fundamentally changed. With the Competition Commission of Mauritius (CCM) launching its first-ever formal market inquiry into the sector, the focus has moved from medical standards to the “hidden” mechanics of the healthcare market.

The central question is no longer just about the quality of care, but the fairness of the cost. From “preferred-provider networks” that potentially sideline smaller clinics to the complex legal risks of vertical integration — where a single entity owns both the insurer and the hospital — the private healthcare sector is facing unprecedented scrutiny. This Q&A explores the legal powers of the CCM, the risks of restrictive business practices, and the potential for new, binding transparency rules, etc.

* Apart from the Competition Act 2007, are there specific laws (e.g., Private Health Institutions Act) which currently regulate the commercial conduct and pricing models of private clinics in Mauritius?

The commercial conduct and pricing models of private clinics in Mauritius are primarily regulated by the Private Health Institutions Act 1989, which is frequently updated to manage the sector. As of April 2026, the sector is under increased scrutiny, with the Competition Commission of Mauritius launching a market inquiry under the Competition Act 2007, specifically looking at high costs and lack of price transparency.

* What would constitute ‘reasonable grounds’ under the Competition Act 2007 for the Commission to intervene in a market where no specific illegal act has yet been proven?

Under the Competition Act 2007 of Mauritius, the Competition Commission can intervene in a market based on “reasonable grounds” even without proving a specific illegal act like a hard-core cartel. The Act focuses on the effect of conduct on market competition and consumers, allowing for intervention when a “restrictive business practice is occurring or about to occur”.
The Competition Act 2007 empowers the Competition Commission to review a monopoly situation, where the conduct of an enterprise or group of enterprises is likely to prevent, restrict or distort competition or in any other way constitute an exploitation of the monopoly situation.  The CCM can impose structural and behavioural remedies against the abuse of a monopoly situation.

*  The Competition Commission highlights “preferred-provider networks,” where deals between insurers and healthcare providers may sideline smaller clinics. If an insurance company sends patients only to one large hospital group, does this breach competition laws and unfairly disadvantage smaller clinics that aren’t on the preferred list?

Yes, if an insurance company in Mauritius sends patients only to one clinic it can potentially breach competition laws, as it may constitute an anti-competitive practice that disadvantages smaller clinics.
The Competition Commission of Mauritius can specifically investigate whether such “preferred-provider networks” restrict, prevent, or distort competition in the private healthcare.

* What about cases where a single entity owns both an insurance company and a private hospital? What specific legal risks does this pose under the law, particularly the Competition Act? Could such vertical integration lead to conflicts of interest, preferential treatment, or the exclusion of competing healthcare providers?

When a single entity in Mauritius owns both an insurance company and a medical clinic, it creates a vertical integration scenario. Vertical integration occurs when a company controls multiple stages of its supply chain rather than relying on external partners. While not illegal per se, this structure poses significant legal risks under the Competition Act 2007 — particularly concerning the abuse of a monopoly situation and the complexities of merger situations that may restrict market access for competitors.

* If the inquiry uncovers a Restrictive Business Practice (like price-fixing or a cartel), can the Commission use its existing powers to issue directives (orders to stop the behaviour) or even impose financial penalties?

Should an inquiry by the Competition Commission uncover a Restrictive Business Practice — specifically collusive agreements such as price-fixing or cartels — the Commission is empowered to issue directives to halt the behaviour and impose substantial financial penalties.
These interventions, categorized as behavioural or structural remedies, aim to immediately terminate anti-competitive conduct and rectify its market effects. Such measures may include orders to cease illegal agreements, the implementation of price control remedies, or, in extreme cases, mandated divestment of assets.

* Are the ‘policy recommendations’ resulting from a Market Inquiry of the Competition Commission legally binding on private operators, or do they function merely as ‘advocacy’ for government action?

Policy recommendations arising from a Market Inquiry by the Competition Commission are not legally binding on private operators. Instead, they serve as a blueprint for government or regulatory intervention.

The ultimate decision to implement these measures rests with the government, which must weigh competition concerns against broader national priorities, such as social equity or environmental sustainability.

* If the Commission issues new guidelines following this inquiry, what is the legal penalty for a private hospital that fails to comply with them?

Under the Competition Act 2007, non-compliance with the Commission’s orders or directions carries heavy legal and financial risks. Should a clinic fail to adhere to mandated remedies — especially those involving restrictive practices such as cartels, bid-rigging, or the abuse of a monopoly situation — it faces stringent financial penalties. In Mauritius, these fines can reach up to 10% of the enterprise’s turnover for the duration of the breach, highlighting the high stakes of regulatory defiance.

* In various jurisdictions, the regulation of private clinics goes beyond simple licensing of “premises” to more active oversight of “commercial conduct.” Has the time come for the Mauritian authorities to adopt international legislative models that offer mechanisms to regulate pricing, transparency, and competition in light of growing concerns about private healthcare costs?

With the April 2026 inquiry, Mauritian authorities are moving beyond mere safety licensing toward a more robust, international-style oversight of clinic business models. The Commission is now scrutinizing the ‘hidden’ drivers of healthcare costs: market dominance by large groups, a lack of price transparency for patients, and the potential for financial referral incentives to compromise clinical necessity

* Adopting “Hong Kong-style” transparency laws would require clinics to provide a binding estimate for surgeries, while a “Singapore-style” benchmark system could help the Mauritian Ministry of Health rein in costs without the administrative burden of direct price control. What’s your take on that?

A hybrid regulatory framework — fusing Hong Kong’s mandatory transparency laws with Singapore’s medical fee benchmark system — presents a compelling roadmap for our Ministry of Health. This dual approach would allow the State to curb escalating private healthcare costs without the administrative burden of rigid price controls.

By replacing the current ‘price opacity’ with binding estimates and national benchmarks, Mauritius can address the very market failures that triggered the Competition Commission’s landmark inquiry in April 2026

* There are concerns that financial incentives for doctors may be steering referrals toward unnecessary, high-cost procedures. How can regulators address this risk and ensure that medical decisions remain guided by patient welfare rather than profit motives?

To protect clinical integrity, the Competition Commission and Ministry of Health must move toward active commercial oversight. This includes enforcing mandatory conflict disclosures for doctor-owned facilities and auditing practitioners who exceed national averages for high-cost procedures to prevent over-treatment.
Additionally, shifting from volume-based fees to bundled or quality-based payments removes the motive for unnecessary care, while a formal ban on referral kickbacks would eliminate illegal commissions. Finally, requiring binding pre-procedure estimates ensures transparency, preventing clinics from upselling services and allowing patients to make informed, cost-effective choices.

Mauritius Times ePaper Friday 8 May 2026